1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Drug Discovery and Development

Medicine research and development industry reports and statistics

 
  • Currently 3/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
13 votes
Share

Global Drug Discovery and Development Industry

 

The global drug discovery and development industry (part of the wider pharmaceutical industry) involves the discovery and design of drugs through laboratory testing to treat disease and infection. With costs running high and few drugs making it to the market, drug discovery and development leaders are constantly seeking ways to reduce expenditure and boost efficiency.

 

One option companies frequently avail of is the practice of outsourcing sections of the discovery and development process. The global drug discovery outsourcing market is expected to grow from less than $7.5 billion in 2009 to a forecast worth of $18.5 billion in 2015, according to Business Insights. Meanwhile, the global drug discovery technologies market is expected to be worth more than $32 billion by 2012, growing at an annual compound rate in excess of 8%.

 

The industry requires heavy investment with no guarantee of results, including under 1% of discoveries going on to be approved by the US Food and Drug Administration. The process itself can take between 12 and 20 years, and cost over the $1.2 billion mark, reports the Alfred Mann Foundation for Biomedical Engineering.

 

Key Drug Launches (2009 - 2013)

 

Disease area Launched Upcoming
Arrhythmia Brinavess™ (vernakalant)  
  Multaq® (dronedarone)  
Autoimmune Simponi® (golimumab) tofacitinib (JAK inhibitor)
  Stelara™ (ustekinumab)  
Diabetes Nesina® (alogliptin, DPPIV) Bydureon™ (exenatide,GLP-1)
  Onglyza™ (saxagliptin, DPPIV) canagliflozin (SGLT2)
  Victoza® (liraglutide, GLP-1) dapagliflozin (SGLT2)
    lixisenatide (GLP-1)
    Tradjenta™ (linagliptin, DPPIV)
Hepatitis C   Victrelis™ (boceprevir, NS3-4A PI)
    Incivek (telaprevir, NS3-4A PI)
Lupus Benlysta® (belimumab)  
Melanoma Yervoy™ (ipilimumab) vemurafenib
Multiple sclerosis Ampyra® (fampiridine, (oral) laquinimod (oral)
  Gilenya® (fingolimod, (oral) ocrelizumab
    teriflunomide (oral)
Osteoporosis Prolia® (denosumab)  
Thrombosis/Acute coronary syndrome Brilique™ (ticagrelor,  P2T) Eliquis (apixaban, Xa)
  Effient® (prasugrel,  Xa)  
  Pradaxa® (dabigatran  etexilate, Xa)  
Prostate cancer Firmagon® (degarelix) Zytiga™ (abiraterone acetate)
  Jevtana® (cabazitaxel)  
  Provenge® (sipuleucel-T)  

 

Source: IMS Institute for Healthcare Informatics, Apr 2011

 

 

Leading Market Segments

 

It is estimated that high throughput screening will be worth $12 billion by 2012, showing over 7% growth in the preceding five years.

 

Bioanalytical instruments have a forecast worth of $10.5 billion in 2012, demonstrating growth in excess of 9%. It is believed the segment of other technologies should come close to the $4.5 billion mark in 2012. Business Insights estimates the electronic data capture market for clinical trials will pass the $1 billion mark in 2016 at 13% annual growth.

 

 

Process: Drug Testing and Development

 

The steps involved in drug discovery begin with the identification of targets, which are genetic or cellular chemicals that influence disease. Once the target has been isolated, the compounds that may work best on them can in turn be determined. Next, the chosen target’s capacity to act on diseased cells is observed before compounds necessary to create a drug are determined, along with the drug target’s response to the compound. In the next phase compounds are compared and data is compiled to aid biopharmaceutical companies to determine the most promising compound for drug creation.

 

Once a drug has been designed, it enters the preclinical phase of development in which it is tested for up to five years to establish its impact on cells. The drug also undergoes toxicology testing to determine any possible harm to humans. In the clinical phase, drugs are administered to humans to test efficacy and potential side effects before companies seek authorization to market the new drug. Research compiled throughout the process is submitted to the relevant authority as the company awaits approval; this part of the process can last up to two years.

 

Contract Research Organization (CRO) Market Value (2005 - 2010) 

 

 

Industry Leaders

 

  • Charles River Laboratories International is a provider of laboratory animal services, research models and both preclinical and clinical support. In operation for over six decades, the company accompanies hospitals, government research facilities, pharmaceutical and biotechnology firms, and academic establishments around the world throughout the process of drug discovery and development. In August 2011, Charles River reached second quarter sales of $288.3 million, showing minimal year-on-year change. The company’s research models and services segment showed more than 6.5% year-on-year growth, reaching second quarter sales of $178.2 million, an increase of more than $11 million on 2010. However, second-quarter profit from preclinical services dropped more than 9% to just over $110 million. In 2005, the company saw its sales reach $1 billion.

 

  • US-based Covance is a world leader in drug development with a global presence spanning 60 countries. The company, which has over 10,000 employees, has contributed to the development of one-third of prescription drugs being sold through its partnership with biotech and pharmaceutical companies since it was established in 1997. Its yearly profits are just under $2 billion. Covance nonclinical development services include toxicology, analysis and research. In its clinical development activities, Covance has contributed to the development of half of the latest groundbreaking cancer treatments on the market.

 

 

Drug Discovery and Development Industry Trends

 

Growth is expected to continue in the global drug discovery and development market due to increasing demand for pharmaceuticals to treat chronic diseases such as diabetes, cardiovascular disease, mental disorders and cancer.

 

Increasing laboratory automation is speeding the process of drug discovery and development, while technological innovation is facilitating research into the molecular mechanisms of disease. Technologies giving increased support to the industry include gene expression, live cell analysis and RNA interference. In addition, technology platforms used to analyze biomarkers and compound toxicity are likely to prove key for the industry moving forward. These platforms would allow researchers to hone in on markers of disease and minimize harm derived from compounds, thereby increasing a drug’s chances of making it onto the market.

 

Disease area Launched Upcoming
     
Arrhythmia Brinavess™ (vernakalant)  
  Multaq® (dronedarone)  
     
Autoimmune Simponi® (golimumab) tofacitinib (JAK inhibitor)
  Stelara™ (ustekinumab)  
     
Diabetes Nesina® (alogliptin, DPPIV) Bydureon™ (exenatide,GLP-1)
  Onglyza™ (saxagliptin, DPPIV) canagliflozin (SGLT2)
  Victoza® (liraglutide, GLP-1) dapagliflozin (SGLT2)
    lixisenatide (GLP-1)
    Tradjenta™ (linagliptin, DPPIV)
     
Hepatitis C   Victrelis™ (boceprevir, NS3-4A PI)
    Incivek (telaprevir, NS3-4A PI)
     
Lupus Benlysta® (belimumab)  
     
Melanoma Yervoy™ (ipilimumab) vemurafenib
     
Multiple sclerosis Ampyra® (fampiridine, (oral) laquinimod (oral)
  Gilenya® (fingolimod, (oral) ocrelizumab
    teriflunomide (oral)
     
Osteoporosis Prolia® (denosumab)  
     
Thrombosis/Acute coronary syndrome Brilique™ (ticagrelor,  P2T) Eliquis (apixaban, Xa)
  Effient® (prasugrel,  Xa)  
  Pradaxa® (dabigatran  etexilate, Xa)  
     
Prostate cancer Firmagon® (degarelix) Zytiga™ (abiraterone acetate)
  Jevtana® (cabazitaxel)  
  Provenge® (sipuleucel-T)  

 

 

Leading Associations

 

 

You might be interested in these related markets

 

Understand the Drug Discovery and Development Industry Quickly & Get Actionable Data Easily. The Latest Reports with Statistics & Trends from Top Sources
1-10 of about 400 reports

Global Drug Discovery Outsourcing Industry Forecast

  • January 2015
    7 pages
  • Drug Discovery  

  • World  

    United States  

View report >

The future of the Drug Discovery And Development Industry in the US

  • March 2014
    6 pages
  • Drug Discovery  

  • United States  

View report >

Drug Discovery And Development Industry in Europe

  • May 2013
    22 pages
  • Drug Discovery  

    Clinical Trial  

    Clinical Resear  

  • Europe  

    Ireland  

View report >

Drug Development Industry in Japan Forecast

  • January 2013
    10 pages
  • Drug Developmen  

    Pharmaceutical  

  • Japan  

    China  

View report >

Drug Discovery And Development Industry in China and South Korea Forecast

  • January 2013
    6 pages
  • Drug Discovery  

  • China  

    South Korea  

    Australia  

View report >

Drug Discovery And Development Industry in New Zealand

  • January 2013
    13 pages
  • Drug Developmen  

    Drug Discovery  

    Clinical Resear  

  • New Zealand  

View report >

The future of the Clinical Trial Industry in the US

  • June 2015
    2 pages
  • Clinical Trial  

  • United States  

View report >

Clinical Research Market Demand in the US

  • June 2015
    2 pages
  • Clinical Resear  

  • United States  

    North America  

View report >

Pharmacology Industry in China

  • June 2015
    8 pages
  • Pharmacology  

  • China  

View report >


About 1 800 reports

Purchase Reports From Reputable Market Research Publishers
(From € 200 - € 3 720)

Chromatography Resins Market in Drug Discovery by Technique, Hydrophobic Interaction, Size Exclusion, Multi Modal and Others & Geography - Global Market Trends & Forecasts to 2020

Chromatography Resins Market in Drug Discovery by Technique, Hydrophobic Interaction, Size Exclusion, Multi Modal and Others & Geography - Global Market Trends & Forecasts to 2020

  • € 3 720
  • Industry report
  • April 2015
  • by MarketsandMarkets

The market for chromatography resins in drug discovery application is estimated at $238.07 Million in 2014 and is projected to grow at a CAGR of 7.0% between 2015 and 2020. The chromatography resins fo ...

Immunotherapy In Oncology Drug Pipeline Update 2015

June 2015 € 3 418

Multiparameter Patient Monitoring - Pipeline Review, 20 ...

May 2015 € 3 200

Prosthetic Heart Valves - Pipeline Review, 2015

April 2015 € 3 200

Spinal Fusion - Pipeline Review, 2015

April 2015 € 3 200

Peripheral Vascular Stents - Pipeline Review, 2015

April 2015 € 3 200

Respiratory Measurement Devices - Pipeline Review, 2015

April 2015 € 3 200

Remote Patient Monitoring - Pipeline Review, 2015

April 2015 € 3 200

Gene Therapy In Oncology Drug Pipeline Update 2015

June 2015 € 2 093

Erbb Signaling Pathway In Cancer Drug Pipeline Update 2 ...

June 2015 € 2 093

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.